NDA 218614 is the FDA application for TRYNGOLZA (olezarsen). The FDA's Orange Book lists the applicant of record as IONIS PHARMACEUTICALS INC and the first approval on it as Dec 19, 2024. Code name used in development: IONIS-APOCIII-LRx. Owner today: Ionis Pharmaceuticals, Inc. (Nasdaq: IONS).
Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 218614 · Orange Book NDA 218614
| Brand name (FDA) | TRYNGOLZA Orange Book trade name: TRYNGOLZA |
|---|---|
| Active ingredient (FDA) | OLEZARSEN SODIUM |
| Code name | IONIS-APOCIII-LRx Source: Ionis Pharmaceuticals press release, Nov 3, 2021 “Initiated the Phase 3 CORE study of olezarsen (IONIS-APOCIII-LRx) in patients with severe hypertriglyceridemia (sHTG)” |
| FDA applicant of record | IONIS PHARMACEUTICALS INC FDA Orange Book data files as of Nov 13, 2026 |
|---|---|
| Owner today | Ionis Pharmaceuticals, Inc. (IONS) Source: Ionis Pharmaceuticals press release, Dec 19, 2024 “Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved” |
| No. | Trade name | Form; route | Strength | Approved |
|---|---|---|---|---|
| 001 | TRYNGOLZA (AUTOINJECTOR) | SOLUTION;SUBCUTANEOUS | EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) | Dec 19, 2024 |
| 002 | TRYNGOLZA (AUTOINJECTOR) | SOLUTION;SUBCUTANEOUS | EQ 50MG BASE/0.8ML (EQ 50MG BASE/0.8ML) | Jun 24, 2026 |
Drug page: /drug/olezarsen
Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.